Briquilimab, an anti-CD117 antibody, prevents passive systemic anaphylaxis in mice expressing chimeric human/mouse CD117
November 15 2023
LBA4 – Preliminary Data from a Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning Is Well-Tolerated, Facilitates Chimerism and Clearance of Minimal Residual Disease in Older Adults with MDS/AML Undergoing Allogeneic HCT – TCT 2022
April 10 2022
Single-Agent Conditioning with Anti-CD117 Antibody JSP191 Shows Donor Engraftment, Naive Lymphocyte Production, and Clinical Benefit in Patients with Severe Combined Immunodeficiency (SCID) – CIS Meeting 2022
April 1 2022
554 JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naïve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID) – ASH 2021
December 12 2021
5-Azacytidine depletes hematopoietic stem cells and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice
August 27 2021
Early results of phase 1 study of JSP191, an anti-CD117 monoclonal antibody, with non-myeloablative conditioning in older adults with MRD-positive MDS/AML undergoing allogeneic hematopoietic cell transplantation
June 4 2021
LBA5 – Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, with Low Dose Irradiation and Fludarabine in Older Adults with MRD-Positive AML/MDS Undergoing Allogeneic HCT
February 8 2021
249 – Non-Toxic Single Agent Transplant Conditioning with JSP191 (an Anti-CD117 monoclonal antibody) in Infants with Newly Diagnosed Severe Combined Immune Deficiency
February 8 2021
18 – Anti-CD117 Antibody Synergizes with 5-Azacytidine to Augment Engraftment of Hematopoietic Stem Cells in Mice with Sickle Cell Disease
February 8 2021
5-Azacytidine Depletes Hematopoietic Stem Cells and Synergizes with an Anti-CD117 Antibody to Augment Engraftment of Donor Stem Cells in Immunocompetent Mice
November 5 2020